je.st
news
Tag: glaxo
Glaxo gets OK to expand marketing of inhaler drug
2015-05-01 00:31:09| Biotech - Topix.net
GlaxoSmithKline plc says it has received U.S. approval to sell its once-a-day respiratory inhaler Breo Ellipta for a new use in asthma patients ages 18 and older. The expanded approval from the Food and Drug Administration will help Glaxo replace sales of its best-selling product, Advair, which faces generic competition in Europe and pricing pressures in the U.S. Breo Ellipta was originally approved to treat a form of lung disease.
Tags: marketing
expand
drug
glaxo
Glaxo recalls flu vaccine due to potency problem
2015-04-17 20:45:17| Biotech - Topix.net
GlaxoSmithKline is recalling a popular four-in-one flu vaccine distributed throughout the U.S. because its effectiveness can decline over time. The company alerted customers Tuesday that the vaccine can lose potency and fail to adequately protect against some flu strains.
Glaxo weighs compensation changes for U.S. sales team
2015-04-11 17:17:39| Biotech - Topix.net
GlaxoSmithKline PLC, which replaced the head of its struggling U.S. operations in February, is considering changes to its compensation model for sales staff, according to an internal memo obtained by Bloomberg News. A task force is looking at "more comprehensive options to simplify the Patient First program" for incentive pay and will provide a report within a month, Glaxo, based in London, said in an April 1 statement to its U.S. sales employees.
Tags: sales
team
compensation
weighs
Glaxo withdraws MaxiNutrition creatine milk over choking concerns
2015-03-23 23:36:12| Biotech - Topix.net
In-bottle creatine crystallisation is behind a full UK recall of GlaxoSmithKline-owned MaxiNutrition Cyclone Milk products over choking concerns. GSK implemented the recall after customer complaints a spokesperson told us today.
Tags: concerns
milk
choking
creatine
FDA panel backs Glaxo inhaler for adults, not adolescents
2015-03-20 02:54:36| Biotech - Topix.net
The Food and Drug Administration panel of experts voted 18-2 against using the British drugmaker's Breo Ellipta in asthma patients ages 12 to 17. That followed a positive vote of 16-4 supporting the drug's use in asthma patients 18 and up. Breo Ellipta is already approved in the U.S. for a type of chronic lung disease, but Glaxo is hoping to expand the drug's use to the much larger patient population of roughly 37 million Americans with asthma.
Tags: panel
adults
backs
adolescents